| INTRODUCTION
Several studies and meta-analyses have concluded that eradication of hepatitis C virus (HCV) with antiviral therapy reduces the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis C, independent of their fibrosis stage.
1 During the era of interferon-based therapy, patients with a sustained virological response (SVR) including those on combination therapy with pegylated interferon and ribavirin showed both histological improvement through HCV eradication as well as a decrease in the risk of HCC development. 2 Other research concluded that patients achieving SVR through interferon-based therapies who had previously received curative HCC treatment, including local ablation therapy and hepatic resection, had favourable outcomes compared with non-SVR patients. The introduction of the new wave of direct-acting antivirals (DAAs) in 2014, with increased tolerance and effectiveness, was seen as a continuing step forward in the treatment of persons with a history of HCC and thought likely to improve their overall prognosis.
The new, highly effective DAAs were expected to dramatically decrease HCV-related liver disease progression to end-stage liver disease and HCC; however, these optimistic expectations were questioned by an initial report from Spain in 2016. Reig 3 and colleagues reported a "more than expected" early recurrence rate (27.6%) in patients with HCC who received DAA treatment after an initial good response to HCC treatment. This report represented a red flag and opened the door for a debate about the relationship between DAA treatment and HCC recurrence. Reports from
Italy and the United States, both demonstrating and refuting any increase in recurrence following DAAs in varying groups, were released soon after. [4] [5] [6] [7] These initial reports lacked any form of comparative survival analysis between DAA-exposed and nonexposed groups. Subsequently, a comparison of DAA-exposed and nonexposed groups from the French ANRS Hepather cohort, reported by Pol and colleagues, 8 treated DAA exposure as time varying and found no increased risk of recurrence in those exposed to DAAs (HR: 1.21, 95% CI 0.62-2.34). However, this cohort started following future DAA-exposed patients from a median 23 months after the original HCC diagnosis and was criticized for possible underreporting of HCC recurrence. 9 A recent review by Reig et al 10 presents
an overview of the conflicting evidence that has been presented so far in this debate; the types of studies conducted, heterogeneity in the populations included, and variability in the analytical methods used, suggesting that no firm conclusions can yet be drawn on this topic.
HCC is the most common cancer in Egypt, 11 largely due to the country having the highest global prevalence of HCV. 12 Due to the availability of low-cost branded and generic DAAs, the Egyptian
Ministry of Health and the National Committee for the Control of Viral Hepatitis have treated approximately one million Egyptian patients since 2014, with cure rates over 90% using various DAA combinations. 13 Therefore, we examined HCC recurrence within 2 years of initial HCC complete radiological response in an HCV-infected Egyptian cohort, for those who either were or were not given DAAs through use of comparative time-dependent analysis and propensity scoring.
| MATERIALS AND METHODS

| Study design and participants
This study was carried out at one HCC treatment centre in Cairo,
Egypt. Patients of all Barcelona Clinic Liver Cancer (BCLC) stages and prognoses were consulted at this centre through clinical and imaging examinations and those with BCLC stages 0 and A were treated through local ablation procedures; these patients had a maximum of three cancerous lesions, with the largest lesion being <5 cm in diameter. Local ablative procedures available at this centre included the following: radiofrequency ablation (RFA), microwave ablation (MWA), percutaneous ethanol injection (PEI), surgical resection and transarterial chemoembolization (TACE). Following the ablative procedure, patients were followed up after one and 3 months with dynamic computerized tomography (CT) and ultrasound imaging to assess tumour response. After complete radiological response according to modified RECIST criteria (hereafter referred to as "complete radiological response") had been confirmed by a senior radiologist using these imaging techniques at both month one and months three visits, the patients returned for follow-up imaging every three to 6 months, for continued confirmation of complete radiological response until death or loss to follow-up. HCC follow-up imaging at these time intervals was the same for patients both eventually treated and not treated with DAAs. 
| Procedures
For the presented analysis, we applied various inclusion and exclusion We excluded patients who were treated using TACE, as this manoeuvre can be considered palliative. For those who were treated with DAAs during the two-year analysis window, we excluded any patients who had received interferon-containing DAA regimens (ie Sofosbuvir/ Interferon/RBV). We also excluded any patients with early recurrence within 3 months of the date of complete radiological response, to further ensure that newly detected tumours represented true recurrence and were not residual but previously undetected. 
| Statistical analysis
After applying the previously described inclusion and exclusion cri- Incidence rate ratio for DAA treatment exposure was estimated using univariable and multivariable Poisson regression models.
Covariates included in the multivariable model were: time since entry into the cohort (<8 months, 8-16 months and 16-24 months), sex, age (categorized as < or ≥65 years old), baseline Child-Pugh score (categorized as ≤ or >6) and whether or not the patient had ever had gastroesophageal varices (a possible indicator of portal hypertension).
Furthermore, to minimize the effect of confounding by treatment indication, we used inverse probability of treatment weighting (IPTW) using propensity scores. 16 The probability of receiving DAA treatment was modelled based on time since entry into the cohort, sex, age, baseline Child-Pugh score and history of gastroesophageal varices. Stabilized weights were calculated using the R package "ipw".
17
The average treatment effect was estimated using a robust variance F I G U R E 1 Application of inclusion and exclusion criteria to study population with basic recurrence proportions estimator to account for the weighted nature of the sample. IPTW diagnostics were conducted as recommended by Austin and Stuart.
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A sensitivity analysis removed all patients with Child-Pugh score 7
and over the age of 65, as these were DAA treatment ineligibility criteria during the first phase of DAA introduction in Egypt. For a subanalysis, DAA treatment exposure, still treated as time varying, was broken down into three periods: no treatment, the first 6 months after the start of DAA treatment and 6 months after the start of DAA treatment.
A further subanalysis examined the difference between exposure to three-and six-month DAA treatment regimens. All statistical analyses were conducted using R.
| RESULTS
Between January 2013 and May 2016, 129 HCV-infected HCC patients, all BCLC stage A or 0, were consulted and treated with local ablation procedures at the HCC treatment centre in Cairo, Egypt. Of these, the following were excluded: two patients who were treated with TACE; two patients who never achieved a complete radiological response; six patients who had early recurrence of HCC (two of these were already taking DAAs); three patients who were eventually treated with DAA regimens containing interferon. This left us with a total of 116 patients, 53 of whom eventually received DAAs during the two-year analysis follow-up period and 63 who did not ( Figure   S1A ,B).
The DAA-exposed and nonexposed groups were similar in terms of sex, age and diabetes as well as their number of hepatic focal lesions and size of their largest lesion at baseline (Table 1) . No patients in our cohort were alcoholic or had a history of alcoholism.
The Child-Pugh score was lower in those treated with DAAs; 1.9%
of the DAA-exposed group had a score of 7, whilst in the DAA nonexposed group, 17.5% (P = .006) had a score of 7. The ablative manoeuvres performed on patients in both groups were similar-the majority of patients in both groups underwent radiofrequency ablation. The DAA-exposed group received varying all-oral regimens for either three-or six-month periods. SVR12 was confirmed in 77.4% of the DAA-treated patients overall and in 89.2% of patients when excluding those treated with Sofosbuvir/RBV ( 
| DISCUSSION
Our data point to a high (ie almost 4 times) increased rate of recurrence after DAA treatment for patients with a history of successfully treated HCC, when compared to similar patients who were not given DAAs.
This significantly higher rate of recurrence in the DAA-exposed group remained after adjustment for baseline factors and time since HCC complete radiological response through inverse probability weighting, as well as across the sensitivity analyses performed. As far as we know, this is the first propensity scored comparative time-dependent analysis for DAA-exposed and nonexposed patients followed from the moment of HCC complete radiological response.
It has been suggested that rapid changes to the immune surveillance system and/or antitumour response following DAA treatment could be the reason for the apparent increase in HCC recurrence. The necessary assumption of this comparative analysis is that DAA-exposed and nonexposed patients are similar. However, it can be argued that in an era of highly expensive DAA treatments for HCV, it is possible that clinicians systematically choose to treat patients with certain clinical indicators over others; for example, in Egypt, treating patients with better prognoses has been estimated as more cost-effective based on quality-adjusted life expectancy outcomes. T A B L E 2 DAA treatment regimens, end of treatment and SVR12 proportions in the DAA-exposed group (N = 53)
T A B L E 3 Recurrence rates and rate ratios comparing DAA-exposed and nonexposed patients Rate is per 100 person-months; the probability of receiving treatment was modelled using the covariates presented in the table.
Ineligibility for treatment in this case relates mainly to when a patient had a worse prognosis (eg older age, more deteriorated liver function); this was the case for 11 of our patients who had ChildPugh score 7, and two patients who were too old (>65 years), who did not receive DAAs according to the applied treatment protocol at that time. For the remaining 50 patients who did not receive DAAs within our two-year analysis period, 14 eventually received DAAs afterwards, 15 had recurrence within this time and were therefore not eligible, and for 21, the attending hepatologist decided not to recommend treatment at all within the viewed follow-up period.
Although our results cannot approximate a clinical trial in terms of random treatment assignment, we do assess that any underlying differing factors between the groups would likely be negative confounders; we would expect patients with a better prognosis to be treated with DAAs.
One of the biggest strengths of this study was our ability to follow and analyse recurrence depending on eventual DAA exposure in an entire cohort of HCV-positive patients from the moment of HCC complete radiological response. This has not yet been done in any other robust study; the survival analysis performed by Pol et al 8 followed patients from time of "cohort inclusion"; this was a median 1.9 and 1.6 years after HCC diagnosis for DAA-exposed and unexposed groups, respectively. All other currently published papers on this subject report recurrence in DAA-exposed groups after varying median number of months following their HCC complete radiological response. A demonstration of these differences, using some of the first studies published within this debate, can be seen in Table 4 .
The issue with a delayed observation window in these populations is twofold: 1. The biological mechanisms behind early-(within 2 years) and late (> 2 years)-phase recurrence have been reported to differ 
22
In order to draw any interim guidance from the currently published data on this subject, the findings that have been put forth to date should be considered and grouped according to the population included, analysis methods used and the time window of observation for the included patients. Perhaps DAA treatment of surviving patients without any recurrence 2 years after HCC complete radiological response poses no additional risk, whereas administration of DAAs to patients in the first 2 years after HCC complete radiological response should be avoided until clinical trials provide more concrete evidence of their benefit.
T A B L E 4 Previous studies evaluating the association between DAA and frequency of recurrence in patients who achieved complete radiological response following HCC treatment 
